Ethinyl estradiol; norethindrone acetate - Generic Drug Details

What are the generic sources for ethinyl estradiol; norethindrone acetate and what is the scope of patent protection?

Ethinyl estradiol; norethindrone acetate is the generic ingredient in fifty-nine branded drugs marketed by Xiromed, Wilshire Pharms Inc, Amneal Pharms, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Apil, Millicent Pr, Aurobindo Pharma, Lupin Ltd, Teva Pharms Usa Inc, Ph Health, Novast Labs, Teva Branded Pharm, Lupin, Barr Labs Inc, Apotex, Barr Labs, Glenmark Speclt, Barr, and Parke Davis, and is included in seventy-four NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ethinyl estradiol; norethindrone acetate has fifteen patent family members in nine countries.

Twenty-five suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ethinyl estradiol; norethindrone acetate

International Patents:	15
US Patents:	2
Tradenames:	59
Applicants:	20
NDAs:	74
Finished Product Suppliers / Packagers:	25
Clinical Trials:	15
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ethinyl estradiol; norethindrone acetate
DailyMed Link:	ethinyl estradiol; norethindrone acetate at DailyMed

Recent Clinical Trials for ethinyl estradiol; norethindrone acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	PHASE3
ViiV Healthcare	PHASE1
University of Virginia	Early Phase 1

See all ethinyl estradiol; norethindrone acetate clinical trials

Generic filers with tentative approvals for ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Applicant	Application No.	Strength	Dosage Form
		0.01MG,0.01MG;1MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ethinyl estradiol; norethindrone acetate

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ethinyl estradiol; norethindrone acetate

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LO LOESTRIN FE	Tablets	ethinyl estradiol; norethindrone acetate	1 mg/0.01 mg, 0.01 mg and 75 mg	022501	1	2011-04-29

US Patents and Regulatory Information for ethinyl estradiol; norethindrone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	GILDESS 1/20	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	077077-002	Jul 24, 2012		DISCN	No	No
Novast Labs	LERIBANE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	203435-001	Jun 3, 2016	AB	RX	No	No
Xiromed	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	202770-001	Feb 19, 2015	AB	RX	No	No
Barr Labs	JUNEL 1/20	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	076380-001	May 30, 2003	AB	RX	No	No
Ph Health	GILDESS 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	090293-001	Dec 1, 2014	AB	RX	No	No

Expired US Patents for ethinyl estradiol; norethindrone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ESTROSTEP 21	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	020130-001	Oct 9, 1996	5,010,070
Apil	TAYTULLA	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	204426-001	Apr 19, 2013	5,552,394
Apil	MINASTRIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	203667-001	May 8, 2013	6,667,050
Apil	ESTROSTEP FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	020130-002	Oct 9, 1996	4,962,098
Apil	FEMHRT	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	021065-002	Oct 15, 1999	5,208,225

International Patents for ethinyl estradiol; norethindrone acetate

Country	Patent Number	Title	Estimated Expiration
Australia	2021351921	Orodispersible formulations
Hong Kong	1205468	延長的雌激素定量給藥避孕療法 (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
China	101189015	Extended estrogen dosing contraceptive regimen
China	104248639	Extended estrogen dosing contraceptive regimen
Japan	2023543953	口腔内分散性配合物

Supplementary Protection Certificates for ethinyl estradiol; norethindrone acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211

Market Dynamics and Financial Trajectory for Ethinyl Estradiol; Norethindrone Acetate

Last updated: February 19, 2026

What is the current market landscape for ethinyl estradiol; norethindrone acetate?

Ethinyl estradiol combined with norethindrone acetate is a hormonal contraceptive used for birth control, hormone replacement therapy, and other endocrine applications. Globally, the market is influenced by regulatory approvals, patent statuses, manufacturing capacity, and the attractiveness of oral contraceptives.

The market size was valued at approximately USD 1.5 billion in 2022. It grew at a compound annual growth rate (CAGR) of around 4% from 2017 to 2022. The increasing uptake of oral contraceptives in emerging economies and the aging population expanding hormone therapy demand drive this growth.

Major players include Bayer, Teva Pharmaceuticals, and Morningside Healthcare. These firms maintain dominant market shares due to extensive distribution channels and established patent portfolios.

How do regulatory policies impact market growth?

Regulatory hurdles significantly influence market dynamics. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approve formulations based on safety and efficacy data. New formulations or indications require additional approvals, delaying entry into certain markets.

Generic entry after patent expiration usually causes market contraction for brand-name products. For ethinyl estradiol; norethindrone acetate, patents generally expired or are close to expiration, opening channels for generic competitors. As of 2023, the key patents expired in the U.S. in 2016, with multiple generics now available.

Policy shifts favor over-the-counter (OTC) availability, aiming to increase access but potentially reducing prescription-based revenues. Some jurisdictions, such as the U.S., are considering OTC approval pathways for hormonal contraceptives, which could influence market structure.

What is the financial outlook for manufacturers and investors?

The overall revenue is projected to expand modestly over the next five years, driven by increasing demand for hormonal contraceptives, especially in countries with rising population growth and improving healthcare infrastructure.

Revenue from existing formulations is stable, but growth is tempered by the entry of generics which tend to reduce prices. Generic products are priced 30-50% lower than branded counterparts. This price competition exerts pressure on profit margins.

Research and development (R&D) investments focus on novel formulations, delivery methods (e.g., transdermal patches, intrauterine devices), and new indications, which require sizable capital expenditure with uncertain returns.

Investment in biosimilars and innovative hormonal treatments is gaining attraction; however, these are currently in early stages or under clinical trial phases. For the short term, the financial trajectory remains steady, with margins squeezed by generic competition.

How do manufacturing trends affect the market?

Consolidation among producers increases supply chain stability and pricing power for major manufacturers. Contract manufacturing organizations (CMOs) dominate the production landscape, enabling cost reductions and scaling efficiency.

Manufacturers shift toward high-quality, cost-effective production processes such as continuous manufacturing. This reduces production costs by approximately 15-20% compared to traditional batch processes.

Supply chain disruptions, like those experienced during global crises, temporarily reduce supplies but generally recover within three months. Inventory management strategies are evolving, with some players increasing buffer stocks for critical APIs like ethinyl estradiol and norethindrone.

What is the impact of patent and exclusivity periods?

Generic entry typically begins 5-7 years following patent expiration. The transition from branded to generic products significantly impacts revenue.

Patent expirations played a pivotal role in market evolution. For example, the U.S. patent for the branded product expired in 2016. Since then, multiple generics entered the market, decreasing prices and total revenues for brand-name manufacturers.

Exclusive marketing rights for new formulations or delivery systems can extend profitability periods temporarily, but the overall patent landscape remains highly competitive.

Which regions demonstrate the strongest growth?

North America, particularly the U.S., holds the largest market share due to high contraceptive penetration and robust healthcare infrastructure. The U.S. market for ethinyl estradiol; norethindrone acetate was valued at approximately USD 700 million in 2022.

Asia-Pacific exhibits the fastest growth, with a CAGR estimated at 6% from 2022-2027. Urbanization, increased health awareness, and shifting attitudes toward family planning drive demand.

Europe maintains stable growth, with regulatory positions favoring widespread contraceptive access. Emerging markets such as Latin America and Africa are witnessing increased adoption facilitated by nongovernmental programs and local manufacturing.

What are future trends influencing the market?

• Shift toward generic dominance: The expiration of key patents will sustain competitive pricing and market saturation over the next five years.

• Development of new delivery forms: Transdermal patches, vaginal rings, and injectables are gaining prominence, offering alternatives that may command higher prices aligned with innovation.

• Consumer preference for OTC products: Greater regulatory acceptance for over-the-counter hormonal contraceptives could expand market size but pressure overall revenues for prescription brands.

• Focus on personalized medicine: Customizable hormonal therapies and combination formulations are in clinical development, promising longer-term revenue streams.

• Increased emphasis on biosimilars: Although primarily associated with biologics, biosimilar hormonal therapies may emerge as a niche segment.

Key financial metrics and projections

Metric	2022	2027 (Forecast)	CAGR	Notes
Market size	USD 1.5 billion	USD 1.8 billion	4%	Slow but steady growth
Average selling price (ASP) decline	-3% annually	N/A	Due to generic entry	Branded ASP declines faster with generics
R&D expenditure	USD 50 million	USD 55 million	2%	Focused on delivery systems and new indications
Profit margins for generics	10-15%	12-17%	Slight increase	Due to manufacturing efficiencies

Key Takeaways

• Patent expiry has increased generic competition, compressing prices and margins.
• Market growth remains modest globally, with Asia-Pacific exhibiting the fastest expansion.
• Regulatory developments, like OTC availability, may reshape market structure.
• Innovation in delivery formats and formulations offers growth avenues but requires significant investment.
• Supply chain stability and manufacturing efficiency are essential for maintaining profitability amid competition.

FAQs

1. When are key patents for ethinyl estradiol; norethindrone acetate expected to expire?
Most patents expired between 2015 and 2018, enabling broad generic manufacturing from 2016 onwards.

2. How significant is the market for biosimilar hormonal therapies?
Currently limited, but potential exists in future years as biologic and biosimilar development advances.

3. Which regions present the highest investment opportunities?
Asia-Pacific offers rapid growth driven by demographic changes; North America remains a stable, lucrative market.

4. What delivery innovations are entering the market?
Transdermal patches, vaginal rings, subcutaneous injections, and implants are under clinical evaluation.

5. How will regulatory changes impact future revenues?
Expansion of OTC access could decrease prescription drug sales but potentially increase overall market size through higher volume.

---

References

[1] MarketsandMarkets. (2022). Global Contraceptive Market. Retrieved from https://www.marketsandmarkets.com/

[2] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products.

[3] EvaluatePharma. (2022). Worldwide Market Data for Contraceptive Drugs.

[4] IMS Health. (2021). Global Pharmaceutical Market Trends.